abrdn Asia Ltd sells 133,199 shares of Vijaya Diagnostic Centre, cutting stake to 3.24%
The fund sold 133,199 voting shares in an open‑market transaction on 29 June 2026, reducing its holding to 3.33 million shares (3.24% of total).
What Vijaya Diagnostic Centre announced
Vijaya Diagnostic Centre Ltd (the "Target") disclosed that abrdn Asia Limited, acting on behalf of several managed funds, executed an open‑market sale of 133,199 voting shares on 29 June 2026. The filing, made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, was submitted to BSE on 1 July 2026. The transaction reduced abrdn’s shareholding from 3,464,245 shares (3.3667% of the diluted share capital) to 3,331,046 shares (3.2373%).
Details of the open‑market sale
- Acquirer / Person Acting in Concert (PAC): abrdn Asia Limited, on behalf of funds it advises/ manages and related group companies.
- Mode of acquisition/sale: Open market sale.
- Date of transaction: 29 June 2026 (the date of acquisition/sale as per the filing).
- Number of shares sold: 133,199 voting shares.
- Percentage impact: The sale represents a 0.1294% reduction of the total diluted share capital, moving the holding from 3.3667% to 3.2373%.
- Share capital: The equity share capital of Vijaya Diagnostic Centre remained unchanged at Rs 102,896,728 (based on a Rs 1 par value and 102,896,728 issued shares).
Shareholding before and after the transaction
| Detail | Value |
|---|---|
| Holding before sale | 3,464,245 shares (3.3667% of diluted capital) |
| Shares sold | 133,199 shares (‑0.1294% of diluted capital) |
| Holding after sale | 3,331,046 shares (3.2373% of diluted capital) |
| Total equity share capital | Rs 102,896,728 (102,896,728 shares) |
| Mode of transaction | Open market sale |
| Date of transaction | 29 June 2026 |
| Filing date | 1 July 2026 |
| Regulatory basis | SEBI Regulation 29(2) disclosure |
Why this matters for investors
The filing is a statutory disclosure required when a shareholder’s holding crosses the 1% threshold or changes by a material amount. Although the sale does not alter control of Vijaya Diagnostic Centre, it signals a modest reduction in the exposure of abrdn’s managed funds to the diagnostic services business. The unchanged equity share capital indicates that the transaction was purely a secondary market trade, with no fresh capital raised for the company. Investors should note that the diluted share capital figure includes all convertible securities, but the filing reports no warrants or convertible instruments held by abrdn, simplifying the share‑ownership picture.
Conclusion
On 29 June 2026, abrdn Asia Limited sold 133,199 voting shares of Vijaya Diagnostic Centre Ltd in the open market, decreasing its stake to 3.24% of the diluted share capital. The company’s total equity share capital remains at Rs 102.9 crore, and no new shares were issued. The disclosure satisfies SEBI’s requirement for transparency in substantial share‑holding changes and was filed with BSE on 1 July 2026. No further approvals or actions are pending as a result of this secondary market transaction.
Frequently asked questions
Related stocks
Source filing: view original